Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis

DS Investigational Site 525, Philadelphia

DS Investigational Site 517, Washington D.C.

DS Investigational Site 523, Richmond

DS Investigational Site 511, Raleigh

DS Investigational Site 512, Columbus

DS Investigational Site 527, Doral

DS Investigational Site 510, Sunrise

DS Investigational Site 524, Birmingham

DS Investigational Site 513, Louisville

DS Investigational Site 519, Troy

DS Investigational Site 518, Kenosha

DS Investigational Site 514, Skokie

DS Investigational Site 509, Arlington

DS Investigational Site 508, Cypress

DS Investigational Site 507, San Antonio

DS Investigational Site 506, Austin

DS Investigative Site 529, Orem

DS Investigative Site 530, Salt Lake City

DS Investigational Site 502, Los Angeles

DS Investigational Site 501, Santa Monica

DS Investigational Site 504, San Diego

DS Investigational Site 505, San Diego

DS Investigational Site 528, Huntington Beach

DS Investigational Site 516, Santa Ana

DS Investigational Site 521, Medford

DS Investigational Site 526, Grants Pass

DS Investigational Site 101, Graz

DS Investigational Site 203, Augsburg

DS Investigational Site 202, Berlin

DS Investigational Site 208, Berlin

DS Investigational Site 204, Dresden

DS Investigational Site 206, Essen

DS Investigational Site 201, Frankfurt

DS Investigational Site 207, Gera

DS Investigational Site 211, Leipzig

DS Investigational Site 205, Lübeck

DS Investigational Site 210, Mainz

DS Investigational Site 214, Münster

DS Investigational Site 212, Rostock

DS Investigational Site 304, Jūrmala

DS Investigational Site 301, Riga

DS Investigational Site 302, Riga

DS Investigational Site 303, Riga

DS Investigational Site 305, Riga

DS Investigational Site 406, Gdansk

DS Investigational Site 402, Lodz

DS Investigational Site 403, Poznan

DS Investigational Site 405, Warsaw

DS Investigational Site 407, Warsaw

DS Investigational Site 401, Wroclaw